Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

December 5, 2013

Primary Completion Date

February 9, 2016

Study Completion Date

January 26, 2017

Conditions
Primary Open Angle Glaucoma
Interventions
DEVICE

XEN® Gel Stent

The XEN® Gel Stent (XEN45 implant) was placed in the study eye.

PROCEDURE

Cataract Surgery

Participants diagnosed with a cataract elected to have cataract surgery.

Trial Locations (21)

1090

Vienna University, Vienna

1211

University of Geneva, Geneva

5020

University Augenklinik Salzburg, Salzburg

8036

University of Graz, Graz

10100

Clinica Oculistica, Universita' di Torino, Torino

17036

Klinik fur Augenheilkunde, Neubrandenburg

28046

Hospital Universitario La Paz, Madrid

37126

Integrated University Hospital of Verona, Verona

44892

University Eye Clinic Bochum-Langendreer, Bochum

56124

University of Pisa, Pisa

B-3000

University Hospitals Leuven, Leuven

D-60590

Klinik für Augenheilkunde, Frankfurt

04-141

Ophthalmology Department of the Military Health Service Institute, Warsaw

Unknown

Hospital Meixeiro Servicio de Ofthalmologia, Vigo

Hospital Principe de Asturias, Madrid

Unidad Oftalmologica de Caracas, Caracas

ME16 9QQ

Maidstone Hospital Eye, Ear and Mouth Unit, Maidstone

B18 7QH

Birmingham Midland Eye Theaters, Birmingham

EC1V2PD

Moorfields Eye Hospital, London

SE17EH

St. Thomas Hospital, London

WF14DG

Pinderfields Hospital, Wakefield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AqueSys, Inc.

INDUSTRY

NCT02006693 - Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants | Biotech Hunter | Biotech Hunter